<DOC>
	<DOCNO>NCT00098514</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , talotrexin , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase I trial study side effect , best way give , best dose talotrexin treat patient advanced recurrent solid tumor .</brief_summary>
	<brief_title>Talotrexin Treating Patients With Advanced Recurrent Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose talotrexin patient patient advanced recurrent solid tumor . - Determine safety drug patient . - Determine dose-limiting toxic effect drug patient . Secondary - Determine pharmacokinetics drug patient . - Correlate pharmacokinetic parameter drug patient characteristic drug-related toxicity patient . - Determine , preliminarily , antitumor efficacy drug patient . OUTLINE : This open-label , dose-escalation , multicenter study . Patients receive talotrexin IV 5 minute day 1 OR day 1 8 OR day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 1-6 patient receive escalate dos talotrexin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . An additional 6-10 patient treat MTD . Patients follow 1 month . PROJECTED ACCRUAL : A total 20-40 patient accrue study within 9-12 month .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis malignant solid tumor Metastatic inoperable disease No known curative survivalprolonging palliative therapy exist OR fail prior therapy No leukemia No primary CNS tumor No thirdspace fluid collection ( i.e. , pleural effusion , ascites ) Clinically insignificant small pleural peritoneal effusion identify CT scan , MRI , diagnostic test allow No active* brain metastasis , include follow : Evidence cerebral edema CT scan MRI Progression since prior image study Requirement steroids Clinical symptom of/from brain metastasis NOTE : *Treated and/or stable brain metastasis allow provided patient asymptomatic PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 2 month Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 RBC folate ≥ low limit normal Hepatic Bilirubin normal SGOT SGPT ≤ 2.5 time upper limit normal Renal Creatinine clearance ≥ 50 mL/min Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled serious medical psychiatric illness PRIOR CONCURRENT THERAPY : Biologic therapy No prior bone marrow transplantation Chemotherapy More 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) Endocrine therapy See Disease Characteristics Radiotherapy More 3 week since prior radiotherapy No concurrent radiotherapy Surgery At least 3 week since prior surgery Other Recovered prior therapy More 3 week since prior antifolate therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>